Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02252263 · ClinicalTrials.gov registry record · Phase 1

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
7
Study locations

NCT02252263 is a Phase 1 study of Multiple Myeloma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 44 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02252263, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
7
Study locations

Study Summary

To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab or Urelumab in subjects with multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Elotuzumab
  • DRUG Urelumab
  • DRUG Lirilumab

Study Locations (7)

Arkansas

  • University Of Arkansas For Medical Sciences - Little Rock

Maryland

  • The Sidney Kimmel Comprehensive Cancer Center - Baltimore

New York

  • Memorial Sloan Kettering Cancer Center - New York

Ohio

  • The Ohio State University - Columbus

Oregon

  • Oregon Health & Science University - Portland

Pennsylvania

  • University Of Pennsylvania - Philadelphia

Navarre

  • Local Institution - Pamplona

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2014-12-09
Est. Completion 2017-10-10
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02252263

The ClinicalTrials.gov registry entry for NCT02252263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Elotuzumab is the first listed.

NCT02252263 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arkansas, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT02252263 about?

NCT02252263 is a clinical study titled "A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma". To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab or Urelumab in subjects with multiple myeloma.

What is the current status of trial NCT02252263?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2014-12-09. Estimated completion is 2017-10-10.

What conditions does trial NCT02252263 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02252263?

The interventions under investigation include: Elotuzumab (DRUG), Urelumab (DRUG), Lirilumab (DRUG).

Who is sponsoring clinical trial NCT02252263?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02252263 being conducted?

This trial has 7 study locations across Arkansas, Maryland, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.